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Abstract 
T-cell prolymphocytic leukemia (T-PLL) is a rare 
and aggressive post-thymic lymphoid neoplasm 
characterized by recurrent chromosome 
rearrangements that lead to activation of the TCL1A 
(14q32.1) or the MTCP1 (Xq28) genes. In this 
report, we focus on the t(X;14)(q28;q11.2), which is 
thought to occur in approximately 20% of T-PLL 
cases and leads to overexpression of the MTCP1 
gene by relocation to the T-cell receptor alpha/delta 
(TRA/D) located at 14q11.2 locus. A rare variant of 
the t(X;14) is the t(X;7)(q28;q34) also leading to 
overexpression of MTCP1 this time by relocation to 
the T-cell receptor beta (TRB) locus. Approximately 
80% of T-PLL cases, however, are characterized by 
the inv(14)(q11.2q32.1) and variants, which lead to 
the activation of the TCL1A (14q32.1) gene by 
relocation to the TRA/D or TRB gene loci. The 
additional abnormalities in cases with MTCP1 or 
TCL1A related abnormalities are similar and include 
gain of 8q usually in the form of i(8q), as well as 
deletions 6q, 9p, 11q, and 13q. 
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Clinics and pathology 
Note 
These translocations are known to occur in: 
T-cell prolymphocytic leukemia (T-PLL) 
Ataxia telangiectasia (AT) 
Disease 
T-cell prolymphocytic leukemia (T-PLL) 
Phenotype/cell stem origin 
CD4+CD8- (65-70%) CD4+CD8+ (21-25%), or 
CD4-CD8+ (10-13%), CD7+ bright and surface 
CD3 negative in 20% of cases.  
The coexpression of CD4 and CD8 together with 
weak CD3 and strong CD7 expression suggest that 
the T-PLL cell stage of differentiation is between a 
cortical thymocyte and a mature T-cell (Matutes, 
1998). 
Partial karyotype of the t(X;14)(q28;q11.2) 
Etiology 
T-PLL accounts for about 2% of all mature lymphoid 
neoplasms. Most patients are older than 50 years.  
However, some patients aged as young as 30 years 
have been reported. The disease affects more male 
than female patients (3:1 ratio) (Matutes, 1998). 
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The disease is widespread and does not appear to 
have a geographic predilection or racial clustering. 
Clinics 
T-PLL is a rare and aggressive post-thymic 
lymphoid neoplasm characterized by a high white 
cell count (usually >100,000/μL) with associated 
anemia and thrombocytopenia (Magro et al, 1986). 
Often there is infiltration of the bone marrow, spleen, 
liver, lymph nodes, and skin.  
Patients often present with hepatosplenomegaly and 
generalized lymphadenopathy (Matutes et al, 1991). 
The median survival is usually &#60 1 year. 
However, occasional spontaneous remission has 
been reported in some cases.  
Morphologically, T-PLL includes 3 morphologic 
variants: typical, small cell, and cerebriform, all of 
which have a similar clinical course and genetic 
abnormalities (Matutes et al, 1986).  
Approximately 15% of patients may be 
asymptomatic at diagnosis (indolent phase), which 
might persist several years before progression occurs 
(Matutes et al, 1998). 
Cytology 
T-PLL includes 3 morphologic variants: typical, 
small cell, and cerebriform, all of which have a 
similar clinical course and genetic abnormalities. 
Majority (75%) of T-PLL patients have the typical 
variant where the cells show a regular nuclear 
outline; 20% have the small cell variant; and 5% 
have cells with a more irregular nuclear shape 
similar to the cerebriform cells seen in Sezary 
syndrome (Costa et al, 2003). 
 
Cytology of typical T-PLL cells in peripheral blood. Cells are 
medium-sized with regular nuclear outline, single nucleolus, 
and intense basophilic cytoplasm. 
Cytogenetics 
Stimulation with a T-cell mitogen (typically PHA) is 
necessary to obtain metaphase cells for analysis. 
Most cases of T-PLL have a complex karyotype. 
Inversion (14)(q11.2q32.1), which leads to 
juxtaposition of the T-cell receptor TRA/D at 
14q11.2 with the TCL1A gene at 14q32.1, is the 
most common abnormality present in approximately 
70% of cases (Costa et al., 2003. Another 10% of 
patients have the variant t(14;14)(q11.2;q32.1) 
involving the same genes as the inv(14). Both 
aberrations lead to overexpression of the TCL1A 
gene (Mossafa et al., 1994). The t(X;14)(q28;q11.2) 
is present in about 20% of the cases (de Oliveira et 
al., 2009). This translocation juxtaposes the TRA/D 
with the MTCP1 gene at Xq28 and results in 
overexpression of the MTCP1 gene (Madani et al., 
1996; Soulier et al., 1994). Only few cases have been 
reported with the variant t(X;7)(q28;q34) involving 
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MTCP1 and the T-cell receptor beta (TRB), which 
also lead to overexpression of MTCP1 (De 
Schouwer et al., 2000). 
ADDITIONAL ABNORMALITIES Karyotypes are 
complex in most cases. The most common 
abnormalities involve chromosome 8, usually as 
i(8)(q10) in 45% of cases, but also t(8;8)(p12;q11) in 
15% of cases, +8 in 15%, and deletion 8p in 15% of 
cases (Mossafa et al., 1994). Furthermore, frequent 
losses involving 6q, 9p, 11q, 12p, 13q, 17p/TP53, 
and 22q, and frequent gains of 6p and 7q have been 
reported in most complex karyotypes (Matutes et al., 
1991; Costa et al., 2003). Mutations in the ATM 
(ataxia telangiectasia mutated) gene, located in the 
11q22.3 region have been associated with 
inactivation or significantly reduced expression of 
the ATM protein, which is believed to function as a 
tumor suppressor (Stankovic et al., 2001). 
Treatment 
T-PLL is a neoplasm characterized by an aggressive 
course, poor response to conventional chemotherapy 
and a short median survival. Treatment with purine 
analogs and the monoclonal antibody alemtuzumab 
has resulted in significantly higher response rates 
and increased survival (Szuszies et al., 2014). 
However, responses are transient and allogeneic 
hematopoietic progenitor-cell transplantation 
remains the only potential curative option. The 
proportion of patients eligible for transplant is low, 
owing to the older age group of patients, and 
nonmyeloablative transplantation is a promising 
alternative that needs to be explored. 
Disease 
Ataxia telangiectasia (AT) 
Epidemiology 
AT onset occurs in early childhood and has an 
incidence of approximately 1 in 40 000-100 000 live 
births in the United States. AT is seen among all 
races and is most prominent among ethnic groups 
with a high frequency of consanguinity. 
Clinics 
AT is an autosomal recessive disorder caused by 
mutations in the ataxia telangiectasia mutated 
(ATM) gene. Classic ataxia-telangiectasia (A-T) is 
characterized by progressive cerebellar ataxia 
beginning between ages one and four years, 
oculomotor apraxia, choreoathetosis, telangiectasias 
of the conjunctivae, immunodeficiency,  and 
frequent infections. The disease is included in the 
group of chromosome instability syndromes 
associated with an increased risk for malignancy, 
particularly leukemia and lymphoma. AT children 
tend to develop B-cell acute lymphoblastic leukemia 
whereas T-cell acute lymphoblastic leukemia and T-
PLL tend to occur in teenager patients.   
Various carcinomas are reported to occur in adults. 
Diagnosis of AT relies on clinical findings, including 
slurred speech, truncal ataxia, and oculomotor 
apraxia; neuroimaging; and family history. 
Laboratory findings that support the diagnosis 
include: severely depleted levels of intracellular 
ATM protein, elevated serum alpha-fetoprotein 
concentration (Swift, 1990). 
Cytogenetics 
Spontaneous chromatid/chromosome breaks, 
triradials, quadriradials (less prominent phenomenon 
than in Fanconi anemia), telomeric associations. The 
best diagnosis test is on the (pathognomonic) highly 
elevated level (10% of mitoses) of inv(7)(p14q35), 
t(14;14)(q11;q32), and other nonclonal stable 
chromosome rearrangements involving 2p12, 7p14, 
7q 35, 14q11, 14q32, and 22q11 (illegitimate 
recombinations between immunoglobulin 
superfamily genes Ig and TCR); normal level of 
those rearrangements are: 1/500 [inv(14)), 1/200 
(t(7;14)], 1/10 000 (inv(7)) clonal rearrangements 
further occur in 10% of patients, but without 
manifestation of malignancy: t(14;14), inv(14), or 
t(X;14) (Bartram et al., 1976; Taylor et al., 1992; 
Thick et al., 1994). 
Genes involved and 
proteins 




The gene has two ORFs that encode two different 
proteins. The upstream ORF encodes a 13kDa 
protein that is a member of the TCL1 gene family; 
this protein may be involved in leukemogenesis 
(Soulier et al., 1994). The downstream ORF encodes 
an 8kDa protein that localizes to mitochondria. 
Alternative splicing results in multiple transcript 
variants. 
DNA/RNA 
Complex alternative splicing : two donor sites in 
exon 1: transcripts A, the most abundant, ubiquitous, 
splicing from exon 1 to exon 6; transcripts B, rare : 
splicing from exon 1 to exon 2. Initiation of the 
transcription : an alternative site of initiation of the 
transcription in intron 1 has been found in one tumor 
with a translocation breakpoint in intron 1. 
Protein 
- p8 MTCP1: coded by transcripts A, 68 amino acids; 
one domain formed by 3 alpha helices held together 
by two disulphide bridges in an antiparallel coiled-
coil motif.  
- p13 MTCP1: coded by transcripts B, 107 amino 
acids; one domain with a b-barrel topology. 
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The size of TCR alpha/delta (TRA/D) locus is about 
1 Mb. The TRD variable (V) diversity (D) joining (J) 
and constant region genes are situated within the 
TRA locus between the TRA V and the TRA J 
segments. The TRD locus contains three D segments 
and four J segments, whereas the TRA J region spans 
approximately 80 Kb and contains at least 61 
segments. The TRA/D locus is transcribed in a 
centromere to telomere direction. 
DNA/RNA 
The TRD locus contains three D segments and four 
J segments, whereas the TRA J regions span 
approximately 80 Kb and contain at least 61 
segments. The TRA/D locus is transcribed in a 
centromere to telomere direction. 
Protein 
T-cell receptor alpha/delta chain. 




The human TRB locus spans 620 kb and consists of 
82-85 genes. Enhancers sequences have been 
characterized at 5.5 kb 3' from TRBC2. 
DNA/RNA 
The locus contains 2 types of coding elements : TCR 
elements (64-67 variable genes TRBV, 2 clusters of 
diversity, joining and constant segments) and 8 
trypsinogen genes. 
Protein 
T-cell receptor beta chain. 
References 
Bartram CR, Koske-Westphal T, Passarge E. Chromatid 
exchanges in ataxia telangiectasia, Bloom syndrome, 
Werner syndrome, and xeroderma pigmentosum. Ann Hum 
Genet. 1976 Jul;40(1):79-86 
De Schouwer PJ, Dyer MJ, Brito-Babapulle VB, Matutes E, 
Catovsky D, Yuille MR. T-cell prolymphocytic leukaemia: 
antigen receptor gene rearrangement and a novel mode of 
MTCP1 B1 activation. Br J Haematol. 2000 Sep;110(4):831-
8 
Madani A, Choukroun V, Soulier J, Cacheux V, Claisse JF,  
Valensi F, Daliphard S, Cazin B, Levy V, Leblond V, Daniel 
MT, Sigaux F, Stern MH. Expression of p13MTCP1 is 
restricted to mature T-cell proliferations with t(X;14) 
translocations. Blood. 1996 Mar 1;87(5):1923-7 
Mossafa H, Brizard A, Huret JL, Brizard F, Lessard M, 
Guilhot F, Tanzer J. Trisomy 8q due to i(8q) or der(8) t(8;8) 
is a frequent lesion in T-prolymphocytic leukaemia: four new 
cases and a review of the literature. Br J Haematol. 1994 
Apr;86(4):780-5 
Soulier J, Madani A, Cacheux V, Rosenzwajg M, Sigaux F, 
Stern MH. The MTCP-1/c6.1B gene encodes for a 
cytoplasmic 8 kD protein overexpressed in T cell leukemia 
bearing a t(X;14) translocation. Oncogene. 1994 
Dec;9(12):3565-70 
Swift M. Genetic aspects of ataxia-telangiectasia. 
Immunodefic Rev. 1990;2(1):67-81 
Szuszies CJ, Hasenkamp J, Jung W, Koch R, Trümper L, 
Wulf GG. Loss of donor chimerism in remission after 
allogeneic stem cell transplantation of T-prolymphocytic 
leukemia patients following alemtuzumab induction therapy. 
Int J Hematol. 2014 Nov;100(5):425-8 
de Oliveira FM, Tone LG, Simões BP, Rego EM, Marinato 
AF, Jácomo RH, Falcão RP. Translocations 
t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell 
prolymphocytic leukemia. Int J Lab Hematol. 2009 
Aug;31(4):453-6 
Costa D, Queralt R, Aymerich M, Carrió A, Rozman M, 
Vallespí T, Colomer D, Nomdedeu B, Montserrat E, Campo 
E. High levels of chromosomal imbalances in typical and 
small-cell variants of T-cell prolymphocytic leukemia. 
Cancer Genet Cytogenet. 2003 Nov;147(1):36-43 
Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, 
Deng AC. T-cell prolymphocytic leukemia: an aggressive T 
cell malignancy with frequent cutaneous tropism. J Am Acad 
Dermatol. 2006 Sep;55(3):467-77 
Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla 
R, Dearden C, Sempere A, Catovsky D. Clinical and 
laboratory features of 78 cases of T-prolymphocytic 
leukemia. Blood. 1991 Dec 15;78(12):3269-74 
Matutes E. T-cell Prolymphocytic Leukemia. Cancer 
Control. 1998 Jan;5(1):19-24 
Stankovic T, Taylor AM, Yuille MR, Vorechovsky I. 
Recurrent ATM mutations in T-PLL on diverse haplotypes: 
no support for their germline origin. Blood. 2001 Mar 
1;97(5):1517-8 
Taylor AM, Lowe PA, Stacey M, Thick J, Campbell L, Beatty 
D, Biggs P, Formstone CJ. Development of T-cell leukaemia 
in an ataxia telangiectasia patient following clonal selection 
in t(X;14)-containing lymphocytes. Leukemia. 1992 
Sep;6(9):961-6 
Thick J, Mak YF, Metcalfe J, Beatty D, Taylor AM. A gene 
on chromosome Xq28 associated with T-cell 
prolymphocytic leukemia in two patients with ataxia 
telangiectasia. Leukemia. 1994 Apr;8(4):564-73 
This article should be referenced as such: 
Meloni-Ehrig AM. t(X;14)(q28;q11.2) TRA-TRD/MTCP1. 
Atlas Genet Cytogenet Oncol Haematol. 2016; 
20(12):616-619. 
